GPPAD Data Sharing Statement

Sharing anonymized data (data rendered anonymous in such a way that the data subject is not or no longer identifiable) within the scientific community is important for scientific progress that might eventually benefit patients. The Global Platform for Prevention of Autoimmune Diabetes (GPPAD) is committed to open data sharing in compliance with all applicable European and GPPAD Consortium Member State, Data Protection and Privacy Protection laws, rules and regulations.

GPPAD will make anonymized data of the type 1 diabetes risk screening (GPPAD-02) available to the scientific community on a regular basis.

The results and the respective data of the prevention study POInT (Primary Oral Insulin Trial, GPPAD-03) results will also be shared once they become available, no later than twelve months after completion of the trial.

GPPAD provides access to anonymized biobank material gathered from study participants to external investigators. One goal is to make all generated research available in the manner most conducive to furthering scientific research. Study participants’ privacy rights will always be respected.

External investigators must agree to conduct all research activities and manage all Intellectual Property in a manner that ensures open sharing of data as described below within the legal limits. It is the external investigators’ duty to comply with all applicable European, and GPPAD Consortium Member State, Data-Protection and Privacy-Protection Laws, Rules and Regulations then in effect.

Investigators’ obligations include:
a) Deidentified data generated through the use of GPPAD biobank material will be made available publicly no later than twelve months after the completion of the research activities.
b) Data will be maintained by GPPAD Data Share or by a third-party public repository for a period of at least 1 year following the first date on which the data was made publicly available.

Here you can download the following documents:

All manuscripts, abstracts, presentations, and press releases to be reviewed by the Publications & Presentations Committee should be sent to For further information, please contact us.